New hope for rare ovarian cancers: targeted drugs tested in 176 patients

NCT ID NCT04931342

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Oct 31, 2025 · Last updated May 09, 2026 · Updated 30 times

Summary

This study tests several new drugs chosen based on the unique markers of each person's rare ovarian cancer. It includes 176 adults whose cancer has persisted or returned after standard treatment. The goal is to see if these targeted therapies can shrink tumors or slow the disease, while monitoring side effects.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

A.O. U. Consorziale Policlinico di Bari

Bari, Apulia, 70124, Italy
Adana Baskent University Medical Faculty; Oncology

Adana, 01220, Turkey (Türkiye)
Asan Medical Center

Seoul, 05505, South Korea
Baskent Universitesi Ankara Hastanesi; Tıbbi Onkoloji Bölümü

Ankara, 06490, Turkey (Türkiye)
CHU Besançon - Hôpital Jean Minjoz

Besançon, 25030, France
Cabrini Hospital

Malvern, Victoria, 3144, Australia
Centre Eugène Marquis

Rennes, 35042, France
Centre Francois Baclesse

Caen, 14076, France
Centre Leon Berard

Lyon, 69373, France
Groupe Hospitalier Diaconesses

Paris, 75020, France
Gustave Roussy

Villejuif, 94800, France
Gynekologicko-porodnicka klinika

Prague, 120 00, Czechia
Hospital Clinico Universitario Virgen de la Victoria

Málaga, 29010, Spain
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario La Paz

Madrid, 28046, Spain
Hôpitaux Universitaires de Genève

Geneva, 1205, Switzerland
ICO - Site René Gauducheau

Saint-Herblain, 44805, France
IRCCS S. Raffaele

Milan, Lombardy, 20132, Italy
Institut Claudius Regaud

Toulouse, 31059, France
Institutio Catalan De Oncologia

Barcelona, 08908, Spain
Istituto Tumori Napoli

Naples, Campania, 80131, Italy
Kliniken Essen-Mitte Evang. Huyssens-Stiftung, Klinik für Gynäkologie und gynäkologische Onkologie

Essen, 45136, Germany
Koc University Medical Faculty; Department of Gynecology & Obstetrics

Istanbul, 34010, Turkey (Türkiye)
LLC Medscan

Moskva, Moscow Oblast, 119421, Russia
Levine Cancer Institute

Charlotte, North Carolina, 28204, United States
McGill University Health Centre - Glen Site

Montreal, Quebec, H4A 3J1, Canada
Ohio State University

Columbus, Ohio, 43210, United States
Policlinico Universitario Agostino Gemelli

Rome, Lazio, 00168, Italy
Princess Margaret Cancer Center

Toronto, Ontario, M5G 1Z5, Canada
Samsung Medical Center

Seoul, (0)6351, South Korea
Seoul National University Hospital

Seoul, 03080, South Korea
Severance Hospital, Yonsei University Health System

Seoul, 03722, South Korea
Texas Oncology - Gulf Coast

The Woodlands, Texas, 77380, United States
UCSF Helen Diller Family CCC

San Francisco, California, 94158, United States
University College London Hospitals NHS Foundation Trust - University College Hospital

London, NW1 2PG, United Kingdom
University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States
University of Washington - Seattle Cancer Care Alliance

Seattle, Washington, 98109, United States
Universitätsklinikum Mannheim

Mannheim, 68167, Germany
Virginia Oncology Associates

Norfolk, Virginia, 23502, United States
Washington University School of Medicine

St Louis, Missouri, 63108, United States
Western General Hospital

Edinburgh, EH4 2XU, United Kingdom

Conditions

Explore the condition pages connected to this study.

OVARIAN CANCER